Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Lonafarnib and bulevirtide, when used with pegylated interferon, reduced hepatitis delta levels in two studies.
Smoking cessation, a healthy diet, exercise and weight loss could dramatically reduce new liver cancer cases and liver disease deaths.
Experimental therapy led to weight loss and improved biomarkers of liver health.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
The treatment improved ALT liver enzymes, fat accumulation in the liver, insulin resistance and blood lipid levels.
The dietary supplement is derived from an Asian plant and has effects similar to opioids.
This includes people who use drugs, those with psychiatric disorders and those with a history of alcohol use.
A pooled analysis of numerous clinical trials and real-world studies reached this conclusion.
Nonetheless, half of people with NAFLD were able to reach a 5% weight loss goal using a very low energy diet.
The new, minimally invasive outpatient procedure targets a part of the small intestine that plays a key role in diabetes.
Well-tolerated insulin sensitizer may play a role in the treatment of fatty liver disease.
Consistent use of medication-assisted treatment for opioid use disorder can apparently reduce this risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.